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Case Number 8
Congenital Neuroblastoma
Dillon Mintoff & Christine Mizzi 
Reviewed by: Dr. J. Mizzi MD, MRCP, MRCPCH
Case summary:
Demographic details:
Baby D, female, Swieqi
Baby D is a 3-day-old baby girl who was noted to have abnormal posture and paucity of movement of 
the left foot. Examination revealed flaccid weakness of the left lower limb. The rest of the neurological 
examination was normal. MRI revealed an extramedullary extradural intracanalicular lesion extending 
from caudal to the 10th thoracic vertebral body to L4 and a paraspinal mass from level of L1 to L4 
vertebral bodies which was in continuity with the intracanalicular mass through the right L1/L2 neural 
foramen. This was diagnosed as congenital dumbbell neuroblastoma. 
Presenting Complaint:
Left foot flaccid paralysis and dorsiflexion weakness since birth.
History of Presenting Complaint:
Baby D is a 3-day-old baby girl. She was born at 38+2 weeks gestation by normal vaginal delivery. Her 
birth weight was 3.36kg, which is on the 50th centile. Her weight was appropriate for gestational age. 
Her parents noted that the baby was not moving her left lower limb. Clinical examination revealed flaccid 
paralysis of the left lower limb. The rest of the neonatal and neurological examination was normal. 
Past medical and surgical history: 
The patient has no previous medical or surgical history.
Drug history:
Drug Dosage Frequency Type Reason
Paracetamol 30mg QID Analgesic Pain relief
Family history: 
Mother suffered two miscarriages before giving birth to Baby D. 
Systemic inquiry: 
Apart from the left lower limb paralysis, Baby D was completely healthy on neonatal examination. 
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Current therapy: 
 
Baby D is currently receiving therapy at Great Ormond Street Hospital for Children in London.
Discussion of results of general and specific examinations:
General examination: The patient looked comfortable at rest and did not appear to have any dysmorphic 
features. The patient weighed  3.10kg. She was noted to be slightly plethoric but not jaundiced. 
Examination of the cardiovascular system revealed normal heart sounds (S1+S2+0) and a radial pulse 
rate of 150 beats per minute. The femoral arteries were palpated and there was a normal liver edge. The 
lungs were clear, with air entry on the left equal to that on the right. Respiratory rate was 40 breaths per 
minute. The hips were symmetrically abducted. Galiazzi, Barlow and Ortolani tests were negative. 
Neurological examination: Upper limbs: Normal tone, power and sensation.
                                            Trunk: Normal tone.
                                                 Lower limbs: Right side: normal tone, power and sensation. Left side: flaccid 
weakness below left knee with foot drop and inversion. The knee jerk was equivocal and the ankle jerk 
could not be elicited. The left leg seemed to be thinner than the right but had the same length. The anal 
sphincter was intact. The bladder was not distended and there was no leakage of urine. 
Differential diagnosis:
• Birth trauma
• Tumours: Neuroblastoma
                          Schwannoma 
                          Paraganglioma
                          Ganglioneuroblastoma
                          Ganglioneuroma
                          Glioblastoma 
Diagnostic procedures:
Laboratory exams:
Test: Complete Blood Count
Justification for test: To exclude bone marrow involvement from a possibly malignant lesion
Results: White blood cell count: 9.10 x 109/L 
              Neutrophils: 7.5 x 109/L (High)
              Lymphocytes: 8.49 x 109/L
              Monocytes: 2.29 x 109/L (High)
              Eosinophils: 0.73 x 109/L
              Basophils: 0.13 x 109/L (High)
              Red Cell Count: 5.60 x 109/L 
              Haemoglobin: 19.2 g/dL 
              Haematocrit: 53.6% 
              Mean Cell Volume: 95.5 fL
              Mean Cell Hb: 34.2 pg (High) 
              Mean Cell Hb concentration: 35.8 g/dL 
              Red Cell distribution Width: 17.9% (High) 
              Platelets: 233 x 109/L 
              Mean Platelet volume: 9.2 fL 
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              Reticulocytes: 208.10 x 109/L (Low)
             Serum Urea: 8 mmol/L
             Serum Creatinine: 79 mmol/L 
             Serum Sodium: 145 mmol/L
             Serum Potassium: 5.45 mmol/L (High)
             Serum Chloride: 105.5 mmol/L 
             Serum Bilirubin: 193.00 umol/L
Conclusion: The blood results were normal overall, with the slight abnormalities being insignificant. 
                     Other laboratory tests which could have been included, given this case in particular, 
                     are LFTs to show any involvement of the liver in case of metastases, along with urine 
                     catecholamine metabolites, neuron specific enolase and LDH as tumour markers.
Instrumental exams:
Test: X-ray of left lower limb.
Justification for test: To exclude any trauma or abnormalities in the lower limb, which could possibly
                                  explain the paralysis.
Result: No pathology noted.
Conclusion: The paralysis is not due to a lesion in the lower limb itself. 
Test: MRI head.
Justification for test: To exclude an upper motor neuron lesion in the right motor cortex, which could
                                  possibly give rise to left lower limb paralysis. Although the weakness in the limb
                                      was flaccid and the reflexes were absent, suggesting a lower motor neuron problem, 
                                  this test was still justified as a motor cortical lesion may present with hypotonia
                                  and absent reflexes in the acute stages.
Result: The brain and CSF spaces showed normal intensity. No focal lesion was seen. 
Conclusion: The lower limb motor defect is not the result of a brain lesion. 
Test: MRI whole spine. 
Justification of test: To identify any lesion in the spinal cord which could be the cause of left lower limb 
                                 paralysis. 
Result: An extramedullary extradural intracanalicular lesion extending from caudal to the 10th thoracic
             vertebral body to L4 is noted. This displaced the cord and cauda to the left, taking up most of the
             intracanalicular space. A dumbbell paraspinal mass, 3.2cm (craniocaudally) by 2cm
             (anteroposteriorly), extends from the level of L1 to L4 vertebral bodies. This appears to be in
             continuity with the described intracanalicular mass through the right L1/L2 neural foramen.
             Fullness is also noted at the left L1/L2 neural foramen with no associated extracanalicular 
             extension. (See figures 1 to 6).
Conclusion: There is a paraspinal tumour which has extended to the spinal canal and caused spinal cord
                      compression, leading to left lower limb paraplegia. Histological confirmation of the tumour 
                     was not done locally because Baby D was referred to a tertiary centre for further
                     investigations where a biopsy specimen was taken at laparoscopy. 
Therapy:
Drug Dosage Frequency Type Reason
Paracetamol 30mg QID Analgesic Pain relief
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Diagnosis:
 
Diagnosis: Congenital Neuroblastoma 
Neuroblastoma is the commonest malignant neoplasm in foetuses and neonates and the second commonest 
solid tumour in children, following brain tumours5. It has an incidence of 1 in 7000 live births11. 96 % 
of cases occur before the age of 10 years2. More young children die of neuroblastoma than any other 
cancer11. 
                 
                             Figure 1                               Figure 2 
MRI spine. Fig 1 shows an extramedullary extradural lesion to extend from caudal to the 10th thoracic 
vertebral body to L4. Figure 2 shows a 3.2cm (craniocaudally) x 2cm (anteroposteriorly) paraspinal 
mass extending from L1 to L4 vertebral body.
Neuroblastoma is a malignant embryonic tumour derived from the primordial neural crest cells. These 
cells eventually inhabit the sympathetic ganglia along the neural tube and the adrenal medulla. Since 
both of these produce cathecholamines they can be used as a biomarker for diagnosis of neuroblastoma. 
Neuroblastoma can arise anywhere along the migratory path of the neural crest cells. The most common 
site of primary tumour at presentation is the adrenal gland, followed by the retroperitoneum, paraspinal 
ganglia, posterior mediastinum and with the least common being the pelvis and cervical region5. In this 
particular case, the tumour evolved from the paravertebral ganglia which link with the spinal cord. As 
the dumbbell neuroblastoma grew, it infiltrated the intervertebral foramina and compressed the spinal 
cord and the intraspinal part of the spinal nerves with possible involvement of the vertebral bodies, 
which eventually gave rise to the paraplegia noted on neonatal examination. The incidence of intraspinal 
involvement from peripheral neuroblastoma extension is between 6% and 24%10. Although in this 
particular case, the spinal neuroblastoma was in the lumbar area, the thoracic spine is the most frequent 
level of spinal compression3.
The majority of neuroblastoma cases are sporadic. Amplification and overexpression of the MYCN proto-
oncogene occurs in approximately 20% of neuroblastomas. MYCN gene codes for N-myc protein which 
controls the cell cycle and several microRNAs1. In such sporadic cases, there may also be alterations in the 
p53 pathway and amplification and polymorphism of the MDM2 oncogene. Familial tumours represent 
only 1-2% of cases. They are transmitted in an autosomal dominant fashion with incomplete penetrance, 
with germline mutation in Phox2b and ALK. ALK is critical in the development of the nervous system and 
Phox2b is involved in the formation of cells of the sympathoadrenal lineage11. Familial cases can present 
with two or more neuroblastoma tumours in different sites. Most probably, congenital neuroblastoma is 
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multifactorial, having both an environmental and a genetic input in its aetiology7. It is associated with 
cardiac defects in 20% of cases4.
Neuroblastoma consists of undifferentiated small round-shaped sympathetic cells with scanty cytoplasm, 
hyperchromatic nuclei and indistinct nucleoli. These cells are called neuroblasts and are surrounded by 
neutopil12. Neuroblastoma is one of the small, round, blue cell tumours of childhood (SRBCT)11. The 
neuroblasts may form clusters called Horner–Wright rosettes which are characteristic of neuroblastoma. 
Calcification and schwannian stroma are also sometimes seen12. 
           
                                 Figure 3                                                                               Figure 4
Figure 3 and 4 show the masses described in figure 1 and 2 in coronal section
Neuroblastoma has a range of clinical presentations. It can present as an indolent abdominal or chest 
mass. If it has infiltrated bone it can present with pallor secondary to anaemia, pain or a limp. The 
rare cervical neuroblastomas can present with Horner’s syndrome, a neck mass, stridor and dysphagia. 
Periorbital ecchymosis, proptosis and blindness occur with metastases to the orbital bones11. Spinal 
neuroblastomas give back or radicular pain, sensory deficits, motor deficits and sphincteric dysfunctions3. 
Paraneoplastic syndrome is another presentation of neuroblastoma, specifically opsoclonus-myoclonus 
ataxia, hypertension, flushing, tachycardia, sweating (in adrenal tumours) or intractable diarrhoea (as a 
result of VIP secretion), irritability, vomiting and loss of appetite12. The main site of metastases is the 
liver5. Sometimes neuroblastoma is asymptomatic and discovered incidentally during imaging for other 
reasons12. 
           
                                  Figure 5                                       Figure 6
Figures 5 and 6 show the masses described in figure 1 and 2 in transverse section
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Poor prognostic factors in neuroblastoma are the presence of MYCN gene, deletion of 11p23, poor 
differentiation, advanced stage, diploid tumour (rather than hyperploid), noncystic, diagnosis after birth 
as opposed to antenatal diagnosis, age greater than 18 months, a high mitosis-karyorrhexis index (MKI), 
poor stromal maturity, high serum levels of lactate dehydrogenase, neuron specific enolase and ferritin 
and a low ratio of vanillylmandelic acid to homovanillic acid5,6,12,13. 
The International Neuroblastoma Risk Group Staging System (INRGSS) is used to stage neuroblastoma. 
It is based on risk factors identified by imaging at diagnosis, biopsies and laboratory tests. Stage L 
includes a localised tumour that does not involve vital structures and is confined to one body component. 
Stage L2 refers to a locoregional tumour with the presence of one or more image-defined risk factors. 
Stage M means that there are distant metastasis11. Cytogenetics of neonatal tumours are different to those 
of older children, which explains their different clinical behaviour and the better prognosis7. Taking this 
into consideration, such cases are classified as stage MS which refers to metastatic disease in children 
younger than 18 months in whom the secondaries are limited to the skin, liver and bone marrow. Low-
risk neuroblastoma patients have a 5-year survival rate of 95%, whereas with high risk groups this falls 
to 30-50%11.
It is thought that foetuses presenting with neuroblastoma have a better outcome than if the disease occurs 
later on in childhood4. This is because children older than 1 year usually turn out to have extensive 
metastases at presentation which tends to progress despite intensive treatment2. On the other hand, if 
congenital or diagnosed before the age of 1, the tumour is usually localised8. Moreover, neuroblastoma 
in neonates tends to have a normal MYCN copy number and a hyperdiploid DNA index, both of which 
indicate a good prognosis5. However, although survival with dumbbell neuroblastoma appears to be 
good in many cases, neurological outcome is usually poor8. The most common neurological deficit is 
irreversible flaccid paralysis of lower limbs that does not respond to therapy5. When the patient presents 
with paraplegia, as was the case with this particular baby, it is almost always irreversible3.
Final treatment and follow ups: 
Although neuroblastoma is the commonest extra-cranial tumour in childhood, it is still a rare disease. 
The rarity of this disease means that there are few controlled trials researching the management of this 
condition6. It is know that the clinical behaviour varies from spontaneous regression to widespread 
disseminated disease11. Therefore, expectant management is not suggested for neonates with neuroblastoma 
because the natural history of the disease is unpredictable4. Baby D is currently receiving therapy at Great 
Ormond Street Hospital for Children in London. 
Treatment of neuroblastoma is usually a combination of chemotherapy, radiotherapy and surgical 
resection9. The stage of the tumour is one of the most important factors in choosing treatment. As a general 
rule, resection alone is sufficient for early low-risk tumours. Chemotherapy is added in intermediate-risk 
tumours, or it may be used before surgery to reduce the size of the tumour and facilitate resection. High-
risk tumours are treated with surgery and chemotherapy and bone marrow transplantation if exceedingly 
resistant12. 
Dumbbell neuroblastoma with spinal cord compression is, in many cases, unresectable. Decompressive 
laminectomy is mainly performed in those cases of recent onset neurological dysfunction10. 
With regards to chemotherapy for unresectable disease, the following drugs may be given:
• Akylating agents - cyclophosphamide, ifosfamide
• Platinum compounds - cisplatin, carboplatin
• Topoisomerase II inhibitors – etoposide, doxorubicin
• Vincristine 
• Busulfan and melphalan are sometimes used during stem cell transplant12
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Radiotherapy targeting the primary tumour is used for high-risk patients following chemotherapy. It is 
also useful as palliative therapy for bone metastases and hepatomegaly12. There is a lower recurrence rate 
associated with radiation therapy given before or after bone marrow transplantation9. The most common 
sites of relapse are bone and bone marrow11.
In the future, this patient may be given an additional treatment modality which is autologous stem cell 
transplant for consolidation which helps to re-populate the bone marrow after chemotherapy13. Also, 
immunotherapy and retinoids are used for maintenance11. Immunotherapy is the use of a monoclonal 
antibody ch14.18 which binds to the ganglioside GD2 on the surface of many neuroblastoma cells. This 
is usually done after a stem cell transplant13. Retinoic acid is used as a form of differentiation therapy. 
There are several complications associated with treatment for neuroblastoma and for other tumours 
in general. The kidneys are vulnerable due to toxicity of cisplatin chemotherapy and radiotherapy9. In 
this case, kidney damage due to pressure effects by the paraspinal mass is also possible. If surgery is 
attempted on this patient, there may be significant spinal damage8. Toxic effects of chemotherapy include 
vomiting, diarrhoea, cardiotoxcitity, infertility, deafness, dry desquamation, secondary malignancies, 
derangements in liver function tests and skeletal abnormalities. Radiation may cause skin reactions, 
nausea and vomiting, lethargy, infertility and secondary malignancies. The main complication of stem 
cell transplant is post-transplant shock9. All these complications have to be looked out for during the 
follow-up period. 
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Fact Box 8:
Title: Congenital Spinal Neuroblastoma 
Short description of condition:  Congenital Spinal Neuroblastoma is a solid tumor of the spinal cord which 
arises in utero. Neuroblastoma has an incidence of 1 in 7000 live births, ranking it as the commonest 
neoplasm in fetuses and neonates.
Risk factors:  As the condition arises in utero, pathogenesis of disease in mainly genetic. 
Symptoms:
• Pain 
• Parasthesia 
• Diarrhoea 
• Vomiting 
• Loss of appetite 
Signs: 
• Abdominal / chest mass 
• Paraplegia 
• Hypertension 
• Flushing 
• Tachycardia 
• Sweating
Prevention: There are no specific preventions that can be made, but a diet rich in folate pre-conception is 
associated with a decreased incidence of neuroblastoma. 
NOTE: As you can appreciate, since the condition develops in utero preventive measure are not 
really adequate (Folate is given to every obstetric patient for the prevention of various NT defect, not 
neuroblastoma specifically) and the only signs can be elicted from a newborn  is paraplegia and decreased 
tone. The symptoms above are relevant to those diagnosed at a later stage.
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